Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Esen

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
International Journal of Impotence Research|March 17, 2017
Time-course changes of nLDL-induced erectile dysfunctionN Durmus, A Toylu, S Evcim, et al.
Theriogenology|August 16, 2025
Corrigendum to "Evaluation of serum CA15-3, CEA, Ki-67, PDL-1 and VEGF as a potential diagnostic and prognostic biomarkers in canine mammary tumors" [Theriogenology 247 (2025) 117579 1-9]H E Çolakoğlu, Ç Fidan, M E Alçığır, et al.
Theriogenology|July 21, 2025
Evaluation of serum CA15-3, CEA, Ki-67, PDL-1 and VEGF as a potential diagnostic and prognostic biomarkers in canine mammary tumorsH E Çolakoğlu, Ç Fidan, M E Alçığır, et al.
European Urology|March 12, 2016
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)Marcus J Drake, Christopher Chapple, Ahmet A Esen, et al.
Cancer Research|March 8, 2000
Androgen receptor mutations in prostate cancerM Marcelli, M Ittmann, S Mariani, et al.
World Journal of Urology|July 31, 2024
Evaluation of androgen receptor and androgen receptor splice-variant 7 in bladder cancer; a novel approach into an ancient topicEge Alper Sarıkaya, Peyda Korhan, Canet Incir, et al.
Nigerian Journal of Clinical Practice|May 6, 2025
Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative AnalysisN O Kalkan, G Ucar, S A Esen, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
International Journal of Impotence Research|March 17, 2017
Time-course changes of nLDL-induced erectile dysfunctionN Durmus, A Toylu, S Evcim, et al.
Theriogenology|August 16, 2025
Corrigendum to "Evaluation of serum CA15-3, CEA, Ki-67, PDL-1 and VEGF as a potential diagnostic and prognostic biomarkers in canine mammary tumors" [Theriogenology 247 (2025) 117579 1-9]H E Çolakoğlu, Ç Fidan, M E Alçığır, et al.
Theriogenology|July 21, 2025
Evaluation of serum CA15-3, CEA, Ki-67, PDL-1 and VEGF as a potential diagnostic and prognostic biomarkers in canine mammary tumorsH E Çolakoğlu, Ç Fidan, M E Alçığır, et al.
European Urology|March 12, 2016
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)Marcus J Drake, Christopher Chapple, Ahmet A Esen, et al.
Cancer Research|March 8, 2000
Androgen receptor mutations in prostate cancerM Marcelli, M Ittmann, S Mariani, et al.
World Journal of Urology|July 31, 2024
Evaluation of androgen receptor and androgen receptor splice-variant 7 in bladder cancer; a novel approach into an ancient topicEge Alper Sarıkaya, Peyda Korhan, Canet Incir, et al.
Nigerian Journal of Clinical Practice|May 6, 2025
Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative AnalysisN O Kalkan, G Ucar, S A Esen, et al.
Pageof 9